You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
麗珠集團(000513.SZ):2019年扣非後淨利同比增長25.79% 擬10派11.50元
格隆匯 03-25 19:33

格隆匯3月25日丨麗珠集團(000513.SZ)披露2019年年度報告,報告內,公司實現營業收入93.85億元,同比增長5.91%;歸屬於公司股東的淨利潤13.03億元,同比增長20.39%;歸屬於公司股東的扣除非經常性損益的淨利潤11.92億元,同比增長25.79%;經營活動現金淨流入17.67億元,同比增長39.41%;基本每股收益1.39元,年報推10派11.50元(含税)。

報告期內,集團製劑藥業務共計實現銷售收入62.13億元,佔集團年內營業收入的66.20%,其中化學制劑產品實現銷售收入49.31億元,較上年同比增長16.35%;中藥製劑產品實現銷售收入12.81億元,較上年同比下降16.39%。

2019年,原料藥事業部堅持“保安環、提質量、降成本”的指導思想,持續加強EHS、質量、研發、生產、銷售等各方面的工作。報告期內共實現銷售收入23.50億元,佔集團年內營業收入的25.04%,較上年同比下降0.18%,毛利率較上年增加7.00個百分點,毛利率持續提升,盈利能力繼續增強。

報告期內,集團診斷試劑及設備實現銷售收入7.54億元,佔集團年內營業收入的8.04%,同比增長8.19%。經過多年精耕細作,公司的診斷試劑及設備覆蓋全國各大中型及基層醫院、採供血系統、疾控、第三方體檢中心。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account